Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tyra Biosciences, Inc.

11.50
+0.76007.08%
Post-market: 11.500.00000.00%16:23 EDT
Volume:1.12M
Turnover:12.48M
Market Cap:604.94M
PE:-7.30
High:11.82
Open:10.86
Low:10.46
Close:10.74
Loading ...

Company Profile

Company Name:
Tyra Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
49
Office Location:
2656 State Street,Carlsbad,California,United States
Zip Code:
92008
Fax:
- -
Introduction:
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Directors

Name
Position
Todd Harris
President, Chief Executive Officer and Director
Gilla Kaplan
Director
Isan Chen
Director
Jake Simson
Director
Melissa McCracken
Director
Nina Kjellson
Director
Rehan Verjee
Director
Robert More
Director
Siddarth Subramony
Director

Shareholders

Name
Position
Todd Harris
President, Chief Executive Officer and Director
Daniel Bensen
Chief Operating Officer
Esther van den Boom
Chief Financial Officer
Hiroomi Tada
Chief Medical Officer
Piyush Patel
Chief Development Officer
Robert L. Hudkins
Chief Technology Officer
Ron Swanson
Chief Scientific Officer